• Aliases: GSK1363089, XL880
    • Binds to and selectively inhibits MET and VEGFR2
    • Currently under investigation in phase 2 clinical trial for SCCHN, metastatic gastric cancer, papillary renal cell cancer, and nonsarcomatous GE junction adenocarcinoma
    • Recommended phase 2 dose: 240 mg orally daily for 5 days every 14 days
    • Half-life: â™40 hours
    • Potential side effects: Fatigue, nausea/vomiting, diarrhea, hypertension, proteinuria, increased lipase, increased AST
    (Choueiri et al., 2013)
    Other topics in Targeted and Immunotherapy Agents